Details of Disease

General Information of Disease (ID: DISWA6CS)

• Disease Name: Influenza A virus infection
• Disease Class: 1E30-1E32: Influenza
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISWA6CS: Influenza A virus infection
• ICD Code: ICD-11: ICD-11: 1E30

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amantadine	DMS3YE9	Approved	Small molecular drug	[1]
Flu (pre-) pandemic	DMMB64Z	Approved	NA	[2]
FluLaval	DMN7HOW	Approved	NA	[2]
Rimantadine	DM5DWMU	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 13 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
VX-787	DMM2JXP	Phase 3	Small molecular drug	[4]
CR-6261	DMWK0SU	Phase 2	NA	[5]
CR8020	DMQ47U6	Phase 2	Antibody	[6]
FLU-IGIV	DMD1HSF	Phase 2	Vaccine	[7]
Influenza A virus H7N9 vaccine	DM22AQE	Phase 2	NA	[8]
NP-2	DMLMZ6Q	Phase 2	Small molecular drug	[9]
VAX-102	DMOQ6JG	Phase 2	NA	[10]
VAX-125	DMR57OZ	Phase 2	NA	[11]
VIS410	DM1G6ME	Phase 2	Antibody	[12]
VLP vaccine	DMCERQJ	Phase 2	NA	[13]
IC31 seasonal influenza vaccine	DMEI7AJ	Phase 1	NA	[14]
VAX-161	DMAF4B0	Phase 1	NA	[15]
VIR-2482	DM6LQIU	Phase 1	Antibody	[16]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4128).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019649.
• [4] ClinicalTrials.gov (NCT03376321) A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT02371668) Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model. U.S. National Institutes of Health.
• [6] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [7] ClinicalTrials.gov (NCT03315104) Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Novavax.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028817)
• [10] ClinicalTrials.gov (NCT00921947) Comparative Safety and Immunogenicity of 1.0 Intramuscular (i.m.) and 2.0 Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults. U.S. National Institutes of Health.
• [11] ClinicalTrials.gov (NCT00966238) Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT02468115) Influenza Challenge Study of VIS410 in Healthy Volunteers. U.S. National Institutes of Health.
• [13] Clinical pipeline report, company report or official report of Novavax.
• [14] Clinical pipeline report, company report or official report of Valneva.
• [15] ClinicalTrials.gov (NCT01658800) Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49. U.S. National Institutes of Health.
• [16] ClinicalTrials.gov (NCT04033406) Study of VIR-2482 in Healthy Volunteers. U.S. National Institutes of Health.